In fact, high mutation burden has been shown as a good response predictor to anti-PD-1 therapy in a panel of 12 different human tumors [91,92,93], where rapid expansion of neoantigen-specific T cell clones reactive to tumor neoantigens was observed. The gene discussed is PDCD1; the disease is neoplasm.